Personalized Medicine Could Boost Biotech ETFs
Monday, February 8th, 2010
Tom Lydon (ETF Trends) submits:
Biotechnology is continually advancing and the future may lie in personalized medicine. The biotech sector, along with related ETFs, may see billions in revenue as this market grows in the coming years.
Biotech companies, investors, providers and big pharmaceutical giants are bullish on personalized medicine and have readily entered the field, writes Rebecca Vesely for Modern Healthcare. “Personalized medicine is a way of tailoring medicine to groups of patients and individual patients,” commented Paul Billings, director and chief scientific officer at the new Genomic Medicine Institute. “The return on investment is fewer adverse events, better treatments, shorter hospital visits and better outcomes,” he further adds.
